ReviewMolecular diagnosis & therapy2013
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
Review in Molecular diagnosis & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 182 citations in OpenAlex.
- Her2Scientific reports · 2018Pooled it
- Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).Investigational new drugs · 2021Trial
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Trial
- A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer.Materials today. Bio · 2026Article
- Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions.Gynecologic oncology reports · 2026Review
- Elucidating HER2-directed chimeric antigen receptor (CAR) activation mechanism using homology modeling and all-atom molecular dynamics simulation.Computational and structural biotechnology journal · 2026Article
- Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.International journal of molecular sciences · 2024Review
- PhiHER2: phenotype-informed weakly supervised model for HER2 status prediction from pathological images.Bioinformatics (Oxford, England) · 2024Article
- A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study.Frontiers in immunology · 2024Article
- Therapeutic approaches to enhance natural killer cell cytotoxicity.Frontiers in immunology · 2024Review
- Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients.Molecular & cellular oncology · 2024Article
- Article
- Comparative analysis of Doxycycline and Ayurvedic herbs to target metastatic breast cancer: AnBioMedicine · 2024Article
- Canine lung carcinoma-A descriptive review.Frontiers in veterinary science · 2024Review
- Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making.Gynecologic oncology reports · 2023Article
- Interplay between LncRNAs and microRNAs in Breast Cancer.International journal of molecular sciences · 2023Review
- A review of prognostic and predictive biomarkers in breast cancer.Clinical and experimental medicine · 2023Review
- EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria.Ecancermedicalscience · 2023Article
- A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer.Cancers · 2022Review
- Singular Nuclei Segmentation for AutomaticSensors (Basel, Switzerland) · 2022Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
HER2 or ErbB2 is a member of the epidermal growth factor family and is overexpressed in subsets of breast, ovarian, gastric, colorectal, pancreatic, and endometrial cancers. HER2 regulates signaling through several pathways (Ras/Raf/mitogen-activated protein kinase and phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin pathways) associated with cell survival and proliferation. HER2-overexpressed and/or gene-amplified tumors are generally regarded as biologically aggressive neoplasms. In breast, cervical, endometrial, and ovarian cancer, there have been several studies linking the amplification of the c-erbB2 gene with chemoresistance and overall poor survival. Tyrosine kinase inhibitors and immunotherapy with monoclonal antibodies targeting HER2 hold promise for patients harboring these aggressive neoplasms. Trastuzumab combined with cytotoxic chemotherapy agents or conjugated with radioactive isotopes is currently being investigated in clinical trials of several tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.